LEAC-102 + folinic acid + fluorouracil + oxaliplatin + bevacizumab + cetuximab

This is a **combination investigational regimen** that includes LEAC-102, folinic acid, fluorouracil, oxaliplatin, bevacizumab, and cetuximab, designed for the treatment of advanced colorectal cancer. - **LEAC-102** is an experimental agent being evaluated primarily in combination with standard-of-care chemotherapy and targeted antibodies. - **Folinic acid** (leucovorin) is used to enhance the activity of fluorouracil. - **Fluorouracil** is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting replication. - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis. - **Cetuximab** is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking cell growth and survival pathways. This combination is under **early-phase clinical investigation** for safety, tolerability, and efficacy in subjects with advanced colorectal cancer[3].

Brand names

Eloxatin (for oxaliplatin, component of FOLFOX)Avastin (for bevacizumab)Erbitux (for cetuximab)

Other names

folinic acid, fluorouracil and oxaliplatin (FOLFOX)